Pull to refresh
Logo
Daily Brief
Following
Why Ranks Sign Up
First CLDN18.2 antibody-drug conjugate reaches regulatory review for gastric cancer

First CLDN18.2 antibody-drug conjugate reaches regulatory review for gastric cancer

New Capabilities

Innovent's IBI343 met its Phase 3 goal in previously treated patients, and China's drug regulator accepted the filing under priority review.

Today: Phase 3 meets its goal; China accepts filing

Overview

Advanced gastric cancer that returns after treatment usually kills within about six months. On June 4, 2026, Chinese biotech Innovent Biologics said its drug had slowed that clock in a late-stage trial.

The drug, arcotatug tavatecan, targets a protein called CLDN18.2 and ferries chemotherapy straight into tumor cells. It is the first drug of this design to reach a regulator. China's drug agency has agreed to review it for approval.

Why it matters

Patients out of options for advanced gastric cancer may soon get a treatment that buys more time before the disease grows again.

Questions about this story

No questions yet — be the first to ask.

Key Indicators

~6 mo
Typical survival after first-line treatment fails
Advanced gastric cancer patients often live about six months once initial therapy stops working.
29%
Tumor response rate in Phase 1
Share of CLDN18.2-high patients whose tumors shrank at the recommended dose.
5.5 mo
Median time without disease growth (Phase 1)
Measured in CLDN18.2-high gastric cancer patients before the larger trial.
$11.4B
Maximum value of Takeda licensing deal
Takeda's October 2025 deal for rights to the drug outside Greater China, including milestones.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Play

Exploring all sides of a story is often best achieved with Play.

Log in to play. Track your picks, climb the leaderboards. Log in Sign Up
Predict 4 ways this could play out. Contrarian picks score more — points lock when the scenario resolves. Log in to play
Higher or Lower Two numbers from this story. Guess which is bigger. 5 rounds to set a streak. Log in to play
Connections Sixteen names from the news. Find the four hidden groups of four. Log in to play

People Involved

Organizations Involved

Timeline

October 2022 June 2026

6 events Latest: Today
Tap a bar to jump to that date
  1. Phase 3 meets its goal; China accepts filing

    Today Regulatory

    An interim analysis shows the drug delays disease growth. China's NMPA accepts the application under priority review.

  2. Takeda licenses the drug

    Deal

    Takeda pays $1.2 billion upfront for rights outside Greater China, in a deal worth up to $11.4 billion.

  3. Phase 1 results published in Nature Medicine

    Data

    Across 116 patients, the drug shrank tumors in 29% of CLDN18.2-high cases with little gut toxicity.

  4. FDA approves the first CLDN18.2 drug

    Regulatory

    Astellas's Vyloy becomes the first treatment aimed at CLDN18.2, validating the target IBI343 also hits.

  5. Phase 3 trial launches

    Trial

    The international G-HOPE-001 study opens in China and Japan, testing the drug against investigator-chosen therapy.

  6. First patient dosed in Phase 1

    Trial

    Innovent begins testing IBI343 in advanced gastric and gastroesophageal junction cancer patients.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

2010

Herceptin's ToGA trial in gastric cancer (2010)

The ToGA trial showed trastuzumab, branded Herceptin, helped gastric cancer patients whose tumors carried the HER2 protein. It was the first time a biomarker-defined targeted drug worked in this cancer. Roughly one in five gastric tumors qualified.

Then

Regulators approved trastuzumab for HER2-positive gastric cancer, adding a targeted option to chemotherapy.

Now

Testing tumors for a molecular marker before treatment became standard practice in gastric cancer.

Why this matters now

It set the template Innovent now follows: find a protein on the tumor, select patients who carry it, then aim a drug at it.

January 2021

Enhertu's gastric cancer approval (2021)

The FDA approved trastuzumab deruxtecan, sold as Enhertu, for HER2-positive gastric cancer after earlier treatments failed. Enhertu is an antibody-drug conjugate, the same design as Innovent's drug. It pairs a targeting antibody with a chemotherapy payload.

Then

Patients who had run out of options gained a treatment that shrank tumors more often than chemotherapy.

Now

It proved the conjugate design could beat standard chemotherapy in gastric cancer, fueling a wave of similar drugs.

Why this matters now

Enhertu showed the exact mechanism Innovent uses can work in this disease, lowering the technical doubt around IBI343.

October 2024

Vyloy becomes the first CLDN18.2 drug (2024)

The FDA approved Astellas's Vyloy, an antibody aimed at CLDN18.2, for newly diagnosed advanced gastric cancer. It was the first drug to target this protein. About 38% of gastric tumors carry enough of it to qualify.

Then

Doctors gained a CLDN18.2 option for first-line patients, paired with chemotherapy.

Now

The approval confirmed CLDN18.2 as a real drug target, not just a research idea.

Why this matters now

Vyloy validated the target; Innovent's drug attacks the same protein with a stronger payload aimed at later-stage patients.

Sources

(6)